![Frontiers | Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer Frontiers | Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer](https://www.frontiersin.org/files/Articles/1131342/fphar-14-1131342-HTML-r1/image_m/fphar-14-1131342-g002.jpg)
Frontiers | Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer
![Cancers | Free Full-Text | DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities Cancers | Free Full-Text | DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities](https://pub.mdpi-res.com/cancers/cancers-15-00448/article_deploy/html/images/cancers-15-00448-g001.png?1673852502)
Cancers | Free Full-Text | DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
Conceptual models of erosion and sedimentation in Illinois. Champaign, IL : Illinois State Water Survey , 2 v. : ill. ; 28 c
![PDF) DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities PDF) DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities](https://i1.rgstatic.net/publication/367030123_DNA_Damage_Response_Alterations_in_Ovarian_Cancer_From_Molecular_Mechanisms_to_Therapeutic_Opportunities/links/63beae6d56d41566df59a788/largepreview.png)
PDF) DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
![Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial - The Lancet Oncology Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/d2c25b15-2f11-4698-a532-bf7c183b6a74/gr1.gif)